MPEP Clinical Trials

Size	Price	Qty
10mg	USD 147
1g	USD 1,990

Clinical Trials

A clinical trial sponsored by the University of California, San Diego evaluated a mobile web-based behavioral intervention to improve caregiver well-being, psychological stress, and depressive symptoms. This academically sponsored study has achieved completed recruitment status and was conducted without an assigned clinical phase designation. Overall, this research highlights a clinical focus on therapeutic strategies for stress and depressive symptom management in caregiver populations.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03506945	COMPLETED	Depressive Symptoms; Stress, Psychological	University of California, San Diego	2018-11-01

(data from https://clinicaltrials.gov, updated on 2025-10-24)

Check the MPEP product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

MPEP selectively binds to and antagonizes the metabotropic glutamate receptor subtype 5 (mGluR5) with an IC50 of 36 nM, thereby blocking receptor-mediated phosphoinositide hydrolysis and downstream central glutamatergic signaling pathways. This targeted suppression of mGluR5 activation reduces excitatory neural transmission, producing anxiolytic and antidepressant-like functional effects relevant to managing psychological stress and depressive symptoms.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).